Filing Details

Accession Number:
0001415889-24-021460
Form Type:
4
Zero Holdings:
No
Publication Time:
2024-08-16 16:31:30
Reporting Period:
2024-08-14
Accepted Time:
2024-08-16 16:31:30
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1831828 Vera Therapeutics Inc. VERA Pharmaceutical Preparations (2834) 812744449
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1859453 Marshall Fordyce C/O Vera Therapeutics, Inc.
8000 Marina Boulevard, Suite 120
Brisbane CA 94005
President And Ceo No No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Class A Common Stock Acquisiton 2024-08-14 15,625 $2.90 352,763 No 4 M Direct
Class A Common Stock Disposition 2024-08-14 15,625 $37.56 337,138 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Class A Common Stock Stock Option (Right to Buy) Disposition 2024-08-14 15,625 $0.00 15,625 $2.90
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
858,587 2030-12-15 No 4 M Direct
Footnotes
  1. Includes 1,511 shares of Class A Common Stock acquired under the Issuer's 2021 Employee Stock Purchase Plan on March 13, 2024.
  2. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 23, 2024.
  3. The price reported is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $37.01 to $37.97, inclusive. The Reporting Person will provide upon request to the staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer, full information regarding the number of shares sold at each separate price.
  4. 1/4 of the shares subject to the option vested on December 16, 2021, and 1/48 of the shares vest monthly thereafter.